23andMe Holding Co Equity-NMS: ME

Healthcare

Diagnostics & Research

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$2.25

52W high :

$6.31

1Y :

-44.04%

5Y :

-77.88%

Shares O/S :

288.75 M

Market cap :

658.34 M

What is the share price of 23andMe Holding Co today?

23andMe Holding Co (ME) share price as of April 2, 2023, is $2.28. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of 23andMe Holding Co?

Yes, Indian Investors can invest in the 23andMe Holding Co (ME) Share by opening an international trading account with Angel One.

How can I purchase 23andMe Holding Co shares in India?

Purchasing 23andMe Holding Co (ME) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying 23andMe Holding Co (ME) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of 23andMe Holding Co?

Yes, you can purchase fractional shares of 23andMe Holding Co (ME) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of 23andMe Holding Co?

The market capitalization of 23andMe Holding Co on April 2, 2023, is $658.34 M.

In which sector 23andMe Holding Co belongs?

23andMe Holding Co operates in the Healthcare sector, specifically in the Diagnostics & Research industry.

What documents are required to invest in 23andMe Holding Co stocks?

In order to invest in 23andMe Holding Co (ME) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company's segments include Consumer & Research Services and Therapeutics. The Consumer & Research Services segment comprises its Personal Genome Service (PGS), telehealth business, and research services. Its PGS service provides customers with a suite of genetic reports, including information on customers genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. Its telehealth platform provides patients with access to medical consultation and treatment. Through its research services, it uses its database of genetic and phenotypic information to identify targets for drug development. The Therapeutics segment focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies to improve patients lives.